Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Potential Market Growth Rate of the Anemia Drugs Market?
The anemia drugs market size has grown strongly in recent years. It will grow from $14.72 billion in 2024 to $15.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, rising awareness of iron deficiency anemia, rise in geriatric population, increasing healthcare access in developing regions, and rising demand for targeted therapies.
The anemia drugs market size is expected to see strong growth in the next few years. It will grow to $21.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising healthcare expenditure in emerging markets, growing number of clinical trials in anemia treatment, rise in global prevalence of anemia, and increasing focus on patient-centric drug development. Major trends in the forecast period include advancement in gene therapy for anemia, advanced delivery systems for iron supplements, innovation in erythropoiesis-stimulating agents, advanced diagnostic tools for anemia detection, and innovation in oral anemia treatments.
Claim your free report sample now:
What Are the Primary Growth Contributors in the Anemia Drugs Market?
The increasing focus on personalized medicine is expected to propel the growth of the anemia drugs market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to an individual’s genetic makeup, lifestyle, and environment. The rising focus on personalized medicine is due to advancements in genomic sequencing, which allow for more precise identification of individual genetic variations linked to disease and treatment response. Personalized medicine supports anemia drug production by enabling tailored treatments based on individual genetic profiles, improving drug efficacy, and minimizing adverse effects for better patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, a significant increase from 6 in 2022. Therefore, the increasing focus on personalized medicine drives the growth of the anemia drugs market.
What Are the Major Product/Service Segments in the Anemia Drugs Market?
The anemia drugs market covered in this report is segmented –
1) By Drug Type: Dietary Supplements, Medicines
2) By Therapy Type: Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy, Other Therapy Types
3) By Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Others Anemia Type
4) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
5) By End-User: Clinic, Healthcare, Home Healthcare
Subsegments:
1) By Dietary Supplements: Iron Supplements, Vitamin B12 Supplements, Folic Acid Supplements, Multivitamin And Mineral Supplements
2) By Medicines: Erythropoiesis-Stimulating Agents (ESAs), Iron Chelating Agents, Corticosteroids, Immunosuppressants, Luspatercept And Related Agents
What Are the Future Trends Forecasted for the Anemia Drugs Market?
Major companies operating in the anemia drugs market are focusing on innovative drug developments, such as oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors), to improve iron metabolism and enhance red blood cell production for more effective anemia treatments. Oral HIF-PHI (Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors) are a class of oral medications that target and inhibit prolyl hydroxylase enzymes, which play a role in regulating the hypoxia-inducible factor (HIF) pathway. For instance, in February 2023, GSK plc, a UK-based pharmaceutical company, launched Jesduvroq, a treatment designed to improve red blood cell production and address anemia in adult patients with chronic kidney disease. This innovative anemia drug system features enhanced iron metabolism, improved red blood cell production, and personalized therapies. Jesduvroq is highly effective, boosting red blood cell production and addressing anemia in chronic kidney disease patients by enhancing iron metabolism for better treatment outcomes.
Who Are the Prominent Players in theAnemia Drugs Market?
Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, Regen Biopharma Inc., BioLineRx Ltd., Bluebird Bio Inc.
Get the full anemia drugs market report here:
What Are the Opportunities and Challenges for Anemia Drugs Market Across Regions?
North America was the largest region in the anemia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment